Scholarlink

<p>This study systematically evaluated the adjuvant efficacy of Rehydragel<sup>®</sup> LV alum (AL) and Freund’s adjuvant in enhancing the immunogenicity of an inactivated <i>Pasteurella multocida</i> vaccine in both murine and ovine models. The mice were immunized with vaccines adjuvanted with either AL and Freund’s adjuvant, followed by assessments of humoral and cellular immune responses, organ bacterial burdens, histopathology, and post-challenge survival. Sheep-natural hosts-were immunized with the PM + AL vaccine to validate translational efficacy. The results demonstrated that the PM + AL vaccine elicited significantly higher IgG titers (<i>P</i> &lt; 0.01) and Th2-skewed immune response in mice, characterized by a marked increase in IL-4 and moderate induction of IFN-γ, compared to the Freund’s adjuvant. Immunization with the PM + AL vaccine resulted in 100% survival and complete bacterial clearance in organs post-challenge, whereas PM + Freund’s vaccine resulted in only 40% survival. Histopathology revealed minimal inflammation in PM + AL vaccinated mice. In sheep, PM + AL vaccination elicited robust IgG responses by day 14, complete protection following challenge, elevated lymphocyte stimulation indices (<i>P</i> &lt; 0.01), and increased serum bactericidal activity, without any observable clinical symptoms. By contrast, sheep in the control group exhibited signs of depression and coughing. These findings underscore the importance of validating adjuvant efficacy in target species and highlight the potential of AL as a promising adjuvant for <i>P. multocida</i> vaccines in sheep.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adjuvant screening of an inactivated Pasteurella multocida vaccine in mice and evaluation of its immunogenicity in sheep

  • 期刊论文

  • 发表日期：

    2025年9月23日

查看全文
  • Cheng-cai Zhu,
  • Jia-ying Wu,
  • Ze-kai Wang,
  • Long-hao Wang,
  • Liu-jun Zhang,
  • Kang Yan,
  • Shao-jun He

摘要

This study systematically evaluated the adjuvant efficacy of Rehydragel® LV alum (AL) and Freund’s adjuvant in enhancing the immunogenicity of an inactivated Pasteurella multocida vaccine in both murine and ovine models. The mice were immunized with vaccines adjuvanted with either AL and Freund’s adjuvant, followed by assessments of humoral and cellular immune responses, organ bacterial burdens, histopathology, and post-challenge survival. Sheep-natural hosts-were immunized with the PM + AL vaccine to validate translational efficacy. The results demonstrated that the PM + AL vaccine elicited significantly higher IgG titers (P < 0.01) and Th2-skewed immune response in mice, characterized by a marked increase in IL-4 and moderate induction of IFN-γ, compared to the Freund’s adjuvant. Immunization with the PM + AL vaccine resulted in 100% survival and complete bacterial clearance in organs post-challenge, whereas PM + Freund’s vaccine resulted in only 40% survival. Histopathology revealed minimal inflammation in PM + AL vaccinated mice. In sheep, PM + AL vaccination elicited robust IgG responses by day 14, complete protection following challenge, elevated lymphocyte stimulation indices (P < 0.01), and increased serum bactericidal activity, without any observable clinical symptoms. By contrast, sheep in the control group exhibited signs of depression and coughing. These findings underscore the importance of validating adjuvant efficacy in target species and highlight the potential of AL as a promising adjuvant for P. multocida vaccines in sheep.